3 One-Drug Biotech Wonders

3,441 views

Published on

For Seattle Genetics, Medivation, and Regeneron, one drug is enough.

0 Comments
2 Likes
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
3,441
On SlideShare
0
From Embeds
0
Number of Embeds
1,980
Actions
Shares
0
Downloads
11
Comments
0
Likes
2
Embeds 0
No embeds

No notes for slide

3 One-Drug Biotech Wonders

  1. 1. 3 One-Drug Biotech Wonders
  2. 2. Sometimes One Is Enough • Biotechs often lose money for the first decade or more of their existence. • Going from no revenue to any revenue can drive stock price higher.
  3. 3. Seattle Genetics • Adcetris approved by FDA in 2011 to treat Hodgkin lymphoma and anaplastic large cell lymphoma after prior treatment failure. • Sold outside U.S. and Canada by partner Takeda Pharmaceutical • Receives revenue from partners that use Seattle Genetics’ technology to develop their drugs. Source: Seattle Genetics
  4. 4. Seattle Genetics
  5. 5. • Xtandi approved by FDA in 2012 to treat prostate cancer that has spread and has not responded to chemotherapy • Sold in U.S. with Astellas Pharma • Outside U.S., Astellas pays royalty from the low teens to the low twenties on aggregate net sales of Xtandi Source: Medivation
  6. 6. • Not technically a one-drug company, but other drugs added just $4 million in the third quarter. • Eylea, which treats macular degeneration, contributed $363 million. • Sold by Bayer HealthCare outside the U.S. where Regeneron gets half the profits. Source: Regeneron Pharmaceuticals
  7. 7. Company Date of approval Return since approval Seattle Genetics August 19, 2011 201% Medivation August 31, 2012 61% Regeneron November 18, 2011 465% Check Out These Returns Returns through January 29, 2014.
  8. 8. Biotechs Hoping to Be 1-Drug Wonders • Chelsea Therapeutics (NASDAQ: CHTP) – Developing Northera for neurogenic orthostatic hypotension (dangerously low blood pressure) – FDA decision expected by February 14, 2014 • MannKind (NASDAQ: MNKD) – Developing inhaled insulin Afrezza for diabetics – FDA decision expected by April 15, 2014 • Durata Therapeutics (NASDAQ:DRTX) – Developing Dalvance for bacterial skin infections – FDA decision expected by May 26, 2014
  9. 9. The Motley Fool’s Top Stock For 2014

×